"Stavudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
| Descriptor ID |
D018119
|
| MeSH Number(s) |
D03.383.742.680.705.875 D13.570.230.500.850 D13.570.230.855.875 D13.570.685.705.875
|
| Concept/Terms |
Stavudine- Stavudine
- D4T
- 2',3'-Didehydro-3'-deoxythymidine
- 2',3' Didehydro 3' deoxythymidine
- 2',3'-Didehydro-2',3'-dideoxythmidine
|
Below are MeSH descriptors whose meaning is more general than "Stavudine".
Below are MeSH descriptors whose meaning is more specific than "Stavudine".
This graph shows the total number of publications written about "Stavudine" by people in this website by year, and whether "Stavudine" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 4 | 2 | 6 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 3 | 5 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 7 | 10 |
| 2006 | 0 | 1 | 1 |
| 2007 | 3 | 4 | 7 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
Below are the most recent publications written about "Stavudine" by people in Profiles.
-
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure. J Pediatric Infect Dis Soc. 2020 Feb 28; 9(1):6-13.
-
Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors. J Virol. 2017 12 01; 91(23).
-
Community outreach programs and major adherence lapses with antiretroviral therapy in rural Kakamega, Kenya. AIDS Care. 2018 06; 30(6):696-700.
-
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Pediatr Infect Dis J. 2015 Apr; 34(4):376-82.
-
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. PLoS One. 2014; 9(9):e106525.
-
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15; 207 Suppl 2:S70-7.
-
Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion. AIDS. 2013 Jun 01; 27(9):1397-401.
-
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012; 17(8):1521-31.
-
High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 2012 Nov 23; 12:183.
-
Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry. Cytometry B Clin Cytom. 2013 Jan-Feb; 84(1):55-8.